SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Hence then, the article about antengene receives clinical trial approval in australia for phase i attract study of atg 201 cd19 x cd3 tce in b cell related autoimmune diseases was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases )
Also on site :
- In 1940, Hattie McDaniel became the first African American to win an Oscar and had to sit at a segregated table; the Academy replaced her lost statuette in 2023
- ‘Southern Charm’s Taylor Ann Green and Gaston Rojas Look Coupled-Up on ‘Below Deck’ as She Eyes a Bravoleb Match for Fraser
- ‘River Monsters’ Star Jeremy Wade Announces Major Return Nearly 10 Years After Fan-Favorite Show Ended: ‘I’m Back’